CA-3E
16.11.2023 15:01:34 CET | Business Wire | Press release
Headquartered in Europe with a global reach, Chemycal’s suite of software and data solutions enable global enterprises to navigate the ever-evolving regulatory backdrop by making complex chemical and product management decisions in a more informed and confident manner. Chemycal supports the creation of safer and more sustainable products by providing essential compliance tools and intelligent information, including global regulatory news tracking and 360-degree monitoring of regulatory updates, that highlight the impact of local changes on a company’s global portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231113229200/en/
“Chemycal’s offerings cover critical aspects of a customer’s regulatory monitoring activities, from reporting real-time news to delivering actionable product-level insights,” said Greg Gartland, Chief Executive Officer of 3E. “Chemycal’s ability to help global corporations track and comply with increasingly complex regulations aligns with 3E’s purpose to enable a safer, more sustainable world. We look forward to introducing Chemycal’s industry-leading platform and content to our over 5,000 customers globally.”
Heightened regulatory pressures have led to growing customer demand for efficient and reliable compliance solutions. The combined content and coverage from 3E and Chemycal responds to this market need. Chemycal's broad monitoring and content coverage from more than 1,500 regulatory sources, alongside 3E's broad regulatory data and substance coverage, will provide enhanced global horizon scanning capabilities for clients.
Luca Mohammadi, Co-Founder and CTO of Chemycal, said, “We are thrilled to be joining 3E, a company that shares our vision for providing businesses with the vital data, intelligence, and tools to ensure their products can move safely through the value chain to protect people and the environment. Joining 3E will provide our customers an end-to-end suite of global monitoring products to realize our shared vision.”
“We’re excited to join 3E and bring our platforms to a larger audience,” added Lorenzo Zullo, Co-Founder and CEO of Chemycal. “We have found in 3E a leadership team with the necessary passion, scale and resources to further accelerate Chemycal’s impressive historical growth. We share the same vision to better support global industries to address emerging regulatory challenges. Coupling our scalable platform with 3E’s deep regulatory domain expertise creates a powerful combination, which will empower our customers to consistently achieve their compliance goals.”
Chemycal represents 3E’s third acquisition announcement since its separation from Verisk in March 2022.
Shearman & Sterling LLP served as the legal advisor to 3E. Cambrian served as the legal advisor to Chemycal.
About Chemycal
Founded in 2015, Chemycal is a global regulatory monitoring company, pairing advanced software and technology with domain expertise to aggregate chemical and product compliance data. Leveraging its worldwide network of 1,500 sources, the Company maintains a deep library of 35,000+ news summaries and 150,000+ substances and materials, keeping customers up to date with real-time developments relevant to their product portfolio via its advanced content management system and machine learning algorithms. Clients around the world trust Chemycal with the compliance of their products and the continuity of their businesses.
About 3E
For more than 35 years the world’s leading companies have trusted 3E to provide the intelligent compliance solutions they need to ensure safety and sustainability. Unmatched Environmental, Health, Safety and Sustainability (EHS&S) and product compliance expertise empowers clients to improve chemical and workplace safety, product safety and stewardship and supply chain transparency. 3E is deeply committed to serving its more than 5,000 customers worldwide, representing a wide variety of industries and including the world’s largest chemical manufacturers, retailers and pharmaceutical companies. Learn more at www.3Eco.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231113229200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom